Skip to content

Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy

A Research of the Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02361411
Enrollment
1000
Registered
2015-02-11
Start date
2015-02-28
Completion date
2017-03-31
Last updated
2015-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage

Brief summary

The purpose of this study is to 1. Early identify patients based on clinical manifestation, imaging, gene and histology, explore diagnostic tools 2. get gene repertoire of Chinese 3. Build a cerebral amyloid angiopathy (CAA) prospective cohorts, observing the disease history, and exploring prognostic factors of hemorrhage in CAA patients

Detailed description

We recruited consecutive patients with intracerebral hemorrhage(ICH). Clinical data and the results of laboratory tests and CT will be assessed and recorded. All the subjects will get gene tests including many genes related with Aβ and small vessel disease (Next-generation sequencing and target enrichment system) . The result of the MRI Scans including cerebral microbleeds(CMBs)、Cortical superficial siderosis(cSS), white matter change(WMC) and enlarged perivascular spaces (EPVS) will be assessed using scales. Ocular fundus exams such as funduscopy and imaging will be used to assess multiple dot and blot hemorrhages and microaneurysms by ophthalmologist. Mini-mental state examination(MMSE) will be used to assess the cognitive function. Patients who need operation on the hematoma for the treatment will accept a brain tissue pathological exams According to this, a prospective cohort of CAA patients based on clinical manifestation, imaging, gene and histology will be built, and diagnostic tools such as gene and MRI results, etc will be explored. And we will get gene repertoire of Chinese patient with ICH. Then, the subjects will be followed up on 30-day, 3-month, 6-month, and 1-year.The patients' clinical outcome will be assessed , and the results of laboratory tests and therapy will be recorded. Prognostic factors of patients with CAA related ICH will be explored.

Interventions

None listed

Sponsors

Beijing Municipal Science & Technology Commission
CollaboratorOTHER
Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

①diagnosed wiht spontaneous cerebral hemorrhage after the head CT. ② the patients and their family members agreed to participate in this study.

Exclusion criteria

①cerebral hemorrhage caused by traumatic, cerebral infarction, tumor and arteriovenous malformation. ②patients who can not provide reliable information or are considered unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
apolipoprotein E gene polymorphismbaseline

Secondary

MeasureTime frame
CMBs were evaluated using the Microbleed Anatomical Rating Scale (MARS)baseline
a composite outcome including multiple dot and blot hemorrhages and microaneurysms of the fundusbaseline
recurrence of cerebral hemorrhage1 year

Countries

China

Contacts

Primary ContactDongsheng Fan, doctor
dsfan@sina.com+861082266699
Backup ContactQiong Yang, doctor
qwertycn@163.com+861082265694

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026